GlassScriptPhysician profile
Nicholas A Ravvin
NPI 1093278905
$8,095.60
in general payments reported to CMS, 2019-2025
21 companies · $2,749 in 2025
The $2,749 reported for 2025 was more than what 92% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $3,037 · 2024: $2,310 · 2025: $2,749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,204 · Travel and Lodging: $880 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,203.80 |
| Travel and Lodging | $879.65 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $1,391.86 | 2023 | Neurostar Tms Therapy System |
| Abbvie INC. | $1,222.74 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $819.10 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $700.10 | 2023-2025 | Ingrezza |
| Alkermes, INC. | $635.01 | 2023-2025 | Aristada, Lybalvi, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $540.87 | 2023-2025 | Caplyta |
| Lundbeck LLC | $474.81 | 2023-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $412.43 | 2023-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $396.17 | 2023-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $311.78 | 2023-2025 | Auvelity, Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $306.03 | 2023-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $197.65 | 2023-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $180.17 | 2024-2025 | Cobenfy |
| Bausch Health US, LLC | $177.25 | 2023-2025 | Aplenzin, Wellbutrin |
| Janssen Pharmaceuticals, INC | $88.76 | 2023-2025 | Spravato |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $87.71 | 2023-2024 | Nuplazid |
| Sage Therapeutics, LLC | $49.22 | 2023 | |
| Corium, LLC | $32.34 | 2025 | Azstarys |
| Idorsia Pharmaceuticals US INC | $31.28 | 2023 | Quviviq |
| Livanova USA, INC. | $21.68 | 2024 | Vns Therapy Symmetry Model 8103 Generator |
| Almatica Pharma LLC | $18.64 | 2024 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Ravvin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.